Introduction: Suicide is still a major event of human mortality worldwide. Yet human suicide
prediction, prevention and therapeutic systems at this moment are generally ineffective in the
clinic. No diagnostic system is reliable for significantly suicidal prevention and mortality reduction.
As a result, human suicide etiopathologic investigation (especially at genetic/molecular levels in the
clinical settings) is quite necessary. In order to boost human suicide researches, emerging human suicide
diagnostic/treatment study will be transformed from clinical symptom observations into new generations
of candidate drug targets and therapeutics. To achieve this goal, associations between suicidal
etiopathologic identification, genetic/bioinformatics-based diagnostics and putative drug targets must
be exploited than ever before. After all, the interaction and relationships between environmental/
genetic/molecular clues and overall patient’s risk prediction (environmental influences and different
therapeutic targets/types) should be found out.
Conclusion: In the future, effective clinical suicide prediction, prevention and therapeutic systems can
be established via scientific expeditions and causality discovery.
Keywords: Bioinformatics, clinical pharmacology, drug development, environmental influence, human genome, human suicide,
mental disorders, neural pathogenesis.
Rights & PermissionsPrintExport